A New Eye Drug Matches the Gold Standard — With a Catch
A New Eye Drug Matches the Gold Standard — With a Catch
A sustained-release eye therapy has cleared a high bar in wet age-related macular degeneration (wet AMD): in the Phase 3 SOL-1 trial, a single dose of Ocular Therapeutix’s intravitreal axitinib hydrogel (OTX-TKI, planned brand name Axpaxli) maintained vision in a higher proportion of patients than repeated dosing with aflibercept 2 mg, the long-standing anti-VEGF reference product. At week 36, 74% of axitinib-treated patients maintained the prespecified level of visual acuity versus about 56% on aflibercept; the advantage persisted at week 52 (roughly 66% versus 44%). Rescue-free rates and anatomic measures also favoured the hydrogel. Yet the result comes with a catch—the comparator arm performed better than many analysts had modelled, the trial used specific FDA-aligned rescue criteria that differ from everyday clinic practice, and earlier data releases triggered sharp share-price reactions even as the company claimed success.
The Clinical Problem: Treatment Burden in Wet AMD
Wet AMD remains a leading cause of vision loss. Anti-VEGF injections such as aflibercept (Eylea) can preserve or improve vision, but real-world outcomes often lag clinical-trial results because patients miss injections. A therapy that delivers comparable or better disease control with far fewer visits would address a major practical limitation. Axitinib, a tyrosine kinase inhibitor, blocks VEGF signalling inside cells; formulated in a bioresorbable hydrogel, it is designed to release drug over many months after a single intravitreal injection.
SOL-1 Design and Key Results
SOL-1 enrolled treatment-naïve patients with wet AMD. After a short loading phase with aflibercept, participants were randomised to a single axitinib hydrogel injection or continued aflibercept 2 mg. The primary endpoint was the proportion of patients maintaining best-corrected visual acuity at week 36. Axitinib was superior (74% vs 56%). At week 52 the gap remained (66% vs 44%). More patients on axitinib stayed rescue-free, and central subfield thickness and fluid control also favoured the investigational arm. The company has indicated an NDA submission for wet AMD in the fourth quarter of 2026.
The Catch: Comparator Strength and Endpoint Nuance
When earlier SOL-1 data emerged, the aflibercept arm’s performance exceeded some external expectations, narrowing the perceived differentiation and pressuring the stock despite the statistical win. In addition, rescue criteria followed 2023 FDA draft guidance rather than the more flexible thresholds often used in routine practice; this makes the head-to-head comparison cleaner for regulators but harder to translate directly into “how many injections will my patient need.” Vitreous floaters linked to hydrogel resorption were relatively common, though generally mild to moderate, and a small number of immune-related inflammation events resolved without reported endophthalmitis or retinal vasculitis.
What Differentiation Would Mean
If approved with a durability claim supported by the data, Axpaxli could reduce injection frequency for a substantial subset of patients, potentially improving adherence and long-term vision outcomes. A single injection lasting most of a year would also change clinic logistics and, depending on pricing and access, the overall cost of care. The tyrosine-kinase mechanism offers a pharmacologic alternative to repeated large-protein anti-VEGF injections, which may matter for patients who lose response or face high treatment burden.
Competitive Context
The wet-AMD market already includes high-dose aflibercept, faricimab and other agents aiming for extended intervals. Gene therapies and additional sustained-delivery platforms are in late-stage development. Axpaxli’s advantage will be measured not only against the historical 2 mg aflibercept regimen used in SOL-1 but against the evolving standard of care that already stretches dosing for many patients. Real-world evidence and additional trials (including non-inferiority designs with more contemporary comparators) will be needed to define its place.
Outlook
Ocular Therapeutix’s axitinib hydrogel has matched—and on the trial’s primary measure surpassed—the classic anti-VEGF gold standard in a rigorous Phase 3 setting, with durability that could meaningfully cut treatment burden. The catch is that the magnitude of benefit depends on how the comparator is viewed, how rescue rules translate to clinic, and how the product performs against today’s longer-acting anti-VEGF options. An NDA filing later in 2026 will start the regulatory clock; the commercial and clinical verdict will hinge on labelling, safety in broader use, and whether the durability seen in SOL-1 holds up when the drug meets the full spectrum of real-world wet-AMD patients.
Sources
Lactose
Found this useful?
